EGFR and non-small cell lung carcinoma: In this study, osimertinib significantly prolonged progression-free survival (PFS) (median 10.1 versus 4.4 months; hazard ratio (HR] 0.30 (95% confidence interval (CI) 0.23 to 0.41]; P < 0.001) and improved objective response rate (ORR; 71% versus 31%) versus platinum-doublet chemotherapy in patients with EGFR T790M advanced NSCLC, following disease progression on first-line EGFR-TKI therapy7.